GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » ROE %

Icosavax (Icosavax) ROE % : -36.73% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Icosavax ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Icosavax's annualized net income for the quarter that ended in Sep. 2023 was $-88.16 Mil. Icosavax's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $240.05 Mil. Therefore, Icosavax's annualized ROE % for the quarter that ended in Sep. 2023 was -36.73%.

The historical rank and industry rank for Icosavax's ROE % or its related term are showing as below:

ICVX' s ROE % Range Over the Past 10 Years
Min: -53.25   Med: -45.11   Max: -36.97
Current: -43.02

During the past 4 years, Icosavax's highest ROE % was -36.97%. The lowest was -53.25%. And the median was -45.11%.

ICVX's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.1 vs ICVX: -43.02

Icosavax ROE % Historical Data

The historical data trend for Icosavax's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax ROE % Chart

Icosavax Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROE %
- - -53.25 -36.97

Icosavax Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.56 -42.56 -46.98 -47.34 -36.73

Competitive Comparison of Icosavax's ROE %

For the Biotechnology subindustry, Icosavax's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icosavax's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Icosavax's ROE % distribution charts can be found below:

* The bar in red indicates where Icosavax's ROE % falls into.



Icosavax ROE % Calculation

Icosavax's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-91.758/( (278.22+218.162)/ 2 )
=-91.758/248.191
=-36.97 %

Icosavax's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-88.164/( (247.722+232.38)/ 2 )
=-88.164/240.051
=-36.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Icosavax  (NAS:ICVX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-88.164/240.051
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-88.164 / 0)*(0 / 260.161)*(260.161 / 240.051)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0838
=ROA %*Equity Multiplier
=N/A %*1.0838
=-36.73 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-88.164/240.051
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-88.164 / -88.164) * (-88.164 / -101.1) * (-101.1 / 0) * (0 / 260.161) * (260.161 / 240.051)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.872 * N/A % * 0 * 1.0838
=-36.73 %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Icosavax ROE % Related Terms

Thank you for viewing the detailed overview of Icosavax's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Icosavax (Icosavax) Business Description

Traded in Other Exchanges
N/A
Address
1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101
Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Executives
Adam K. Simpson director, officer: Chief Executive Officer C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan officer: Chief Medical Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley officer: Chief Business Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo officer: Chief Financial Officer C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman officer: Chief Scientific Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan officer: EVP, Head of Research & Dev. C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu officer: See Remarks 1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson officer: See Remarks 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil director C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver director C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi 10 percent owner 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p. 10 percent owner GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807

Icosavax (Icosavax) Headlines

From GuruFocus

Icosavax to Participate in the Evercore ISI HealthCONx Conference

By Value_Insider Value_Insider 11-22-2022

Icosavax Provides Corporate Update and Anticipated Milestones for 2023

By Stock market mentor Stock market mentor 01-06-2023